The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Liquid Chromatography−Mass Spectrometry-Based Parallel Metabolic Profiling of Human and Mouse Model Serum Reveals Putative Biomarkers Associated with the Progression of Nonalcoholic Fatty Liver Disease
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in most western countries. Current NAFLD diagnosis methods (e.g., liver biopsy analysis or imaging techniques) are poorly suited as tests for such a prevalent condition, from both a clinical and financial point of view. The present work aims to demonstrate the potential utility of serum metabolic profiling in defining phenotypic biomarkers that could be useful in NAFLD management. A parallel animal model/human NAFLD exploratory metabolomics approach was employed, using ultra performance liquid chromatography-mass spectrometry (UPLC-MS) to analyze 42 serum samples collected from nondiabetic, morbidly obese, biopsy-proven NAFLD patients, and 17 animals belonging to the glycine N-methyltransferase knockout (GNMT-KO) NAFLD mouse model. Multivariate statistical analysis of the data revealed a series of common biomarkers that were significantly altered in the NAFLD (GNMT-KO) subjects in comparison to their normal liver counterparts (WT). Many of the compounds observed could be associated with biochemical perturbations associated with liver dysfunction (e.g., reduced Creatine) and inflammation (e.g., eicosanoid signaling). This differential metabolic phenotyping approach may have a future role as a supplement for clinical decision making in NAFLD and in the adaption to more individualized treatment protocols.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Clark, J. D., Lin, L.-L., Kriz, R. W., Ramesha, C. S., Sultzman, L. A., Lin, A. Y., Milona, N., & Knopf, J. L. (1991) · Cell · doi:10.1016/0092-8674(91)90556-e · Cited by 1,688
A lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss
Dixon, J. B., Bhathal, P. S., Hughes, N. R., & O'Brien, P. E. (2004) · Hepatology · doi:10.1002/hep.20251 · Cited by 727
The plasma lipidomic signature of nonalcoholic steatohepatitis
Puri, P., Wiest, M. M., Cheung, O., Mirshahi, F., Sargeant, C., Min, H., Contos, M. J., Sterling, R. K., Fuchs, M., Zhou, H., et al. (2009) · Hepatology · doi:10.1002/hep.23229 · Cited by 655
Research works printed but not linked: 88
- Reid A. E., 2001, Gastroenterology, 121, 710, 10.1053/gast.2001.27126 · DOI · Paper page
- Clark J. M., 2003, Gastroenterology, 124, 248, 10.1053/gast.2003.50032 · DOI · Paper page
- Marchesini G., 2003, Hepatology, 37, 917, 10.1053/jhep.2003.50161 · DOI · Paper page
- Adams L. A., 2007, Ann. Epidemiol., 17, 863, 10.1016/j.annepidem.2007.05.013 · DOI · Paper page
- Angulo P., 2007, Nutr. Rev., 65, S57, 10.1301/nr.2007.jun.S57-S63 · DOI · Paper page
- Parekh S., 2007, Gastroenterology, 132, 2191, 10.1053/j.gastro.2007.03.055 · DOI · Paper page
- Caldwell S. H., 2004, Gastroenterology, 127, S97, 10.1053/j.gastro.2004.09.021 · DOI · Paper page
- El-Serag H. B., 2004, Gastroenterology, 127, S27, 10.1053/j.gastro.2004.09.013 · DOI · Paper page
- Malhi H., 2008, Semin. Liver Dis., 28, 360, 10.1055/s-0028-1091980 · DOI · Paper page
- Mato J. M., 2007, Hepatology, 45, 1306, 10.1002/hep.21650 · DOI · Paper page
- Mato J. M., 2008, Annu. Rev. Nutr., 28, 273, 10.1146/annurev.nutr.28.061807.155438 · DOI · Paper page
- Tordjman J., 2009, J. Hepatol., 51, 354, 10.1016/j.jhep.2009.02.031 · DOI
- Farrell G. C., 2006, Hepatology, 43, S99, 10.1002/hep.20973 · DOI · Paper page
- Klein S., 2006, Gastroenterology, 130, 1564, 10.1053/j.gastro.2006.01.042 · DOI · Paper page
- Wanless I. R., 1990, Hepatology, 12, 1106, 10.1002/hep.1840120505 · DOI · Paper page
- Marchesini G., 1999, Am. J. Med., 107, 450, 10.1016/S0002-9343(99)00271-5 · DOI · Paper page
- Marra F., 2008, Trends Mol. Med., 14, 72, 10.1016/j.molmed.2007.12.003 · DOI · Paper page
- Oh M. K., 2008, Aliment Pharmacol. Ther., 28, 503, 10.1111/j.1365-2036.2008.03752.x · DOI
- Ratziu V., 2005, Gastroenterology, 128, 1898, 10.1053/j.gastro.2005.03.084 · DOI · Paper page
- Castera L., 2006, Hepatology, 43, 373, 10.1002/hep.21019 · doi:10.1002/hep.21019
- Kotronen A., 2009, Gastroenterology, 137, 865, 10.1053/j.gastro.2009.06.005 · DOI · Paper page
- Poynard T, I.-B. F., 2004, Comp. Hepatol., 4, 10, 10.1186/1476-5926-4-10 · DOI · Paper page
- Imbert-Bismut F., 2004, Clin. Chem. Lab. Med., 42, 323, 10.1515/CCLM.2004.058 · DOI
- Poynard T., 2005, Comp. Hepatol., 4, 10, 10.1186/1476-5926-4-10 · DOI · Paper page
- Poynard T., 2006, BMC Gastroenterol., 6, 34, 10.1186/1471-230X-6-34 · DOI · Paper page
- Morra R., 2007, Expert Rev. Mol. Diagn., 7, 481, 10.1586/14737159.7.5.481 · doi:10.1586/14737159.7.5.481
- Guha I. N., 2008, Hepatology, 47, 455, 10.1002/hep.21984 · DOI · Paper page
- Guha I. N., 2008, Clin. Liver Dis., 12, 883, 10.1016/j.cld.2008.07.010 · DOI
- Nicholson J. K., 2002, Nat. Rev. Drug Discovery, 1, 153, 10.1038/nrd728 · DOI · Paper page
- Nicholson J. K., 1999, Xenobiotica, 29, 1181, 10.1080/004982599238047 · DOI · Paper page
- Gowda G. A., 2008, Expert Rev. Mol. Diagn., 8, 617, 10.1586/14737159.8.5.617 · DOI · Paper page
- Kaddurah-Daouk R., 2008, Annu. Rev. Pharmacol. Toxicol., 48, 653, 10.1146/annurev.pharmtox.48.113006.094715 · DOI · Paper page
- Heijne W. H., 2005, Expert Rev. Proteomics, 2, 767, 10.1586/14789450.2.5.767 · DOI · Paper page
- Varela-Rey M., 2009, Int. J. Biochem. Cell Biol., 41, 969, 10.1016/j.biocel.2008.10.027 · DOI
- Ariz, U.; Mato, J. M.; Lu, S. C.; Martinez Chantar, M. L.Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new?Methods in Molecular Biology;Humana Press:Totowa, NJ, 2010; Vol.593, pp109−36. · DOI
- Martinez-Chantar M. L., 2008, Hepatology, 47, 1191, 10.1002/hep.22159 · DOI · Paper page
- Kotb M., 1997, Trends Genet, 13, 51, 10.1016/S0168-9525(97)01013-5 · DOI · Paper page
- Avila M. A., 2002, Alcohol, 27, 163, 10.1016/S0741-8329(02)00228-8 · DOI
- Corrales F. J., 2002, J. Nutr., 132, 2377S, 10.1093/jn/132.8.2377S · DOI
- Martinez-Chantar M. L., 2002, Am. J. Clin. Nutr., 76, 1177S, 10.1093/ajcn/76.5.1177S · DOI
- Finkelstein J. D., 2007, Clin. Chem. Lab. Med., 45, 1694, 10.1515/CCLM.2007.341 · DOI · Paper page
- Heady J. E., 1975, Cancer Res., 35, 640
- Chen S. Y., 2004, Cancer Res., 64, 3617, 10.1158/0008-5472.CAN-03-3726 · doi:10.1158/0008-5472.can-03-3726
- Luka Z., 2006, Transgenic Res., 15, 393, 10.1007/s11248-006-0008-1 · DOI
- Griffiths W. J., 2007, Eur. J. Mass Spectrom. (Chichester, England), 13, 45, 10.1255/ejms.850 · DOI
- Burton L., 2008, J. Chromatogr., B: Analyt. Technol. Biomed. Life Sci., 871, 227, 10.1016/j.jchromb.2008.04.044 · DOI
- Theodoridis G. G., 2008, Trends Anal. Chem., 27, 238, 10.1016/j.trac.2008.01.008 · DOI · Paper page
- Bedair M. S., 2008, Trends Anal. Chem., 27, 251, 10.1016/j.trac.2008.01.006 · DOI · Paper page
- Wold S, J. E., 1993, 3D-QSAR in drug design, theory, methods, and applications
- Jolliffe I. T., 2002, Principal component analysis
- Bylesö M., 2006, J. Chemometrics, 20, 341, 10.1002/cem.1006 · DOI · Paper page
- Wiklund S., 2008, Anal. Chem., 80, 115, 10.1021/ac0713510 · DOI · Paper page
- Brugger B., 1997, Proc. Natl. Acad. Sci. U.S.A., 94, 2339, 10.1073/pnas.94.6.2339 · DOI · Paper page
- Khaselev N., 2000, J. Am. Soc. Mass Spectrom., 11, 283, 10.1016/S1044-0305(99)00158-0 · DOI
- Han X. G. R. W., 1996, J. Am. Chem. Soc., 118, 451, 10.1021/ja952326r · doi:10.1021/ja952326r
- Houjou T., 2004, Rapid Commun. Mass Spectrom., 18, 3123, 10.1002/rcm.1737 · DOI
- Duce A. M., 1988, Hepatology, 8, 65, 10.1002/hep.1840080113 · DOI · Paper page
- Kharbanda K. K., 2007, J. Hepatol., 46, 314, 10.1016/j.jhep.2006.08.024 · DOI · Paper page
- Ikura Y., 2006, Hepatology, 43, 506, 10.1002/hep.21070 · DOI
- Li Z., 2006, Cell Metab., 3, 321, 10.1016/j.cmet.2006.03.007 · DOI · Paper page
- Nanji A. A., 1981, Clin. Chem., 27, 1954, 10.1093/clinchem/27.11.1954 · doi:10.1093/clinchem/27.11.1954
- Malnick S. D., 1994, Hepatology, 19, 261, 10.1002/hep.1840190142 · doi:10.1002/hep.1840190142
- Vaubourdolle M., 1993, Hepatology, 17, 423, 10.1002/hep.1840170312 · doi:10.1002/hep.1840170312
- Gentile C. L., 2008, J. Nutr. Biochem., 19, 567, 10.1016/j.jnutbio.2007.10.001 · DOI · Paper page
- Kotronen A., 2009, Diabetes, 58, 203, 10.2337/db08-1074 · DOI · Paper page
- Bass N. M., 2010, Hepatology, 51, 4, 10.1002/hep.23458 · DOI
- Kunos G., 2008, Am. J. Physiol. Gastrointest. Liver Physiol., 294, G1101, 10.1152/ajpgi.00057.2008 · DOI
- Six D. A., 2000, Biochim. Biophys. Acta, 1488, 1
- Kudo I., 2002, Prostaglandins Other Lipid Mediat., 68, 3, 10.1016/S0090-6980(02)00020-5 · DOI · Paper page
- Leslie C. C., 1988, Biochim. Biophys. Acta, 963, 476, 10.1016/0005-2760(88)90316-5 · DOI · Paper page
- Schievella A. R., 1995, J. Biol. Chem., 270, 30749, 10.1074/jbc.270.51.30749 · DOI · Paper page
- Pawliczak R., 2004, J. Biol. Chem., 279, 48550, 10.1074/jbc.M408926200 · DOI
- Leslie C. C., 2004, Prostaglandins Leukot. Essent. Fatty Acids, 70, 373, 10.1016/j.plefa.2003.12.012 · DOI
- Hirabayashi T., 2004, Biol. Pharm. Bull., 27, 1168, 10.1248/bpb.27.1168 · DOI · Paper page
- Goetzl E. J., 2001, Prostaglandins Other Lipid Mediat., 64, 11, 10.1016/S0090-6980(01)00104-6 · doi:10.1016/s0090-6980(01)00104-6
- Kita T. K., 1999, Diabetes Res. Clin. Pract., 45, 123, 10.1016/S0168-8227(99)00041-8 · DOI
- Yang L., 2008, Chem. Res. Toxicol., 21, 2280, 10.1021/tx800225q · DOI
- Monte M. J., 2009, World J. Gastroenterol., 15, 804, 10.3748/wjg.15.804 · DOI · Paper page
- Perez M. J., 2009, World J. Gastroenterol., 15, 1677, 10.3748/wjg.15.1677 · DOI · Paper page
- Gilat T., 2003, Hepatology, 38, 436, 10.1053/jhep.2003.50348 · DOI
- Kobayashi N., 2002, Steroids, 67, 827, 10.1016/S0039-128X(02)00036-3 · doi:10.1016/s0039-128x(02)00036-3
- Mari M., 2004, J. Clin. Invest., 113, 895, 10.1172/JCI200419852 · doi:10.1172/jci200419852
- Mari M., 2007, Liver Int., 27, 440, 10.1111/j.1478-3231.2007.01475.x · doi:10.1111/j.1478-3231.2007.01475.x
- Morales A., 2007, Apoptosis, 12, 923, 10.1007/s10495-007-0721-0 · DOI · Paper page
- Engelmann B., 2004, Biochem. Soc. Trans., 32, 147, 10.1042/bst0320147 · DOI · Paper page
- Zoeller R. A., 1999, Biochem. J., 338, 769, 10.1042/bj3380769 · DOI · Paper page
- Tominaga T., 1993, Alcohol Alcohol Suppl., 1, 103, 10.1093/alcalc/28.Supplement_1A.103 · doi:10.1093/alcalc/28.supplement_1a.103
- Xie Z., 2010, Metabolism, 59, 554, 10.1016/j.metabol.2009.08.022 · DOI
Cited by
Modern analytical techniques in metabolomics analysis
Zhang, A., Sun, H., Wang, P., Han, Y., & Wang, X. (2012) · The Analyst · doi:10.1039/c1an15605e · Cited by 877
S-adenosylmethionine in Liver Health, Injury, and Cancer
Lu, S. C., & Mato, J. M. (2012) · Physiological Reviews · doi:10.1152/physrev.00047.2011 · Cited by 554
Self-citationBiomarkers of NAFLD progression: a lipidomics approach to an epidemic
Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., Min, J., Spann, N. J., McDonald, J. G., Kelly, S. L., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p056002 · Cited by 372
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
Pyroptosis: An Inflammatory Link Between NAFLD and NASH With Potential Therapeutic Implications
Beier, J. I., & Banales, J. M. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.017 · Cited by 101
Metadata
- Authors
- Barr, J., Vázquez-Chantada, M., Alonso, C., Pérez-Cormenzana, M., Mayo, R., Galán, A., Caballería, J., Martín-Duce, A., Tran, A., Wagner, C., Luka, Z., Lu, S. C., Castro, A., Le Marchand-Brustel, Y., Martínez-Chantar, M. L., Veyrie, N., Clément, K., Tordjman, J., Gual, P., & Mato, J. M.
- Venue
- Journal of Proteome Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-08-04
- Volume
- 9
- Issue
- 9
- Pages
- 4501-4512
- ISSN
- 1535-3893 (ISSN-L)
- 1535-3907
- OpenAlex
- W2087843153
- Cited by
- 162
- References
- 6
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.